玻璃体切割术后糖尿病黄斑水肿治疗新进展  

Recent research advances in the treatment of diabetic macular edema after vitrectomy

作　　者：李蕴智 安洋 成艾璇 芦志雯 范斌[1] LI Yunzhi;AN Yang;CHENG Aixuan;LU Zhiwen;FAN Bin(Department of Ophthalmology,the Second Hospital of Jilin University,Changchun 130041,Jilin Province,China)

机构地区：[1]吉林大学第二医院眼科,吉林省长春市130041

出　　处：《眼科新进展》2023年第3期249-252,共4页Recent Advances in Ophthalmology

基　　金：吉林省自然科学基金项目(编号:20200201379JC);吉林省教育厅科学技术项目(编号:JJKH20190046KJ)。

摘　　要：糖尿病黄斑水肿(DME)是糖尿病视网膜病变(DR)常见的并发症,而DR患者常因玻璃体积血和视网膜脱离等并发症需要行玻璃体切割术,术后DME的治疗方案随着玻璃体内替代物和药物动力学的改变发生变化,目前该病主要的治疗方案有抗血管内皮生长因子药物、糖皮质激素和阈值下微脉冲激光等。本文就玻璃体切割术后DME的治疗进展进行综述。Diabetic macular edema(DME) is a common complication of diabetic retinopathy(DR). DR patients need vitrectomy because of complications such as vitreous hemorrhage and retinal detachment. The treatment of DME after vitrectomy changes with the changes in vitreous substitutes and pharmacokinetics. At present, the main treatments include anti-vascular endothelial growth factor drugs, glucocorticoids and subthreshold micropulse laser. This article will review the progress in the treatment of DME after vitrectomy.

关 键 词：糖尿病黄斑水肿 玻璃体切割术 抗血管内皮生长因子 糖皮质激素 阈值下微脉冲激光 

分 类 号：R774.5[医药卫生—眼科]